Cancer Screening by A. B. MillerCancer Screening by A. B. Miller

Cancer Screening

EditorA. B. Miller, J. Chamberlain, N. E. Day

Paperback | June 9, 2011

Pricing and Purchase Info

$59.83

Earn 299 plum® points

Prices and offers may vary in store

Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

Screening is regarded as a cost-effective and clinically useful approach for the early diagnosis of several malignancies, especially such common cancers as those of the breast and the cervix. This 1991 is a publication from the Project on evaluation of Screening for Cancer, organized by the International Union Against Cancer (UICC), one of the world's foremost agencies in the field of cancer epidemiology and control. It contains recommendations from the international authorities on cancers for which screening is used. Findings from studies in many countries are presented and evaluated, and methodological issues are also discussed. This is an influential and authoritative statement on the scope of cancer screening. It will be of interest to oncologists, epidemiologists and others in the public health field.
Title:Cancer ScreeningFormat:PaperbackDimensions:458 pages, 9.61 × 6.69 × 0.94 inPublished:June 9, 2011Publisher:Cambridge University PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0521116945

ISBN - 13:9780521116947

Look for similar items by category:

Table of Contents

Preface; Part I. Screening for Breast Cancer: State of the Art on Breast Cancer Screening: 1. Sensitivity and specificity of screening in the UK trial of early detection of breast cancer; 2. Screening for breast cancer in Finland; 3. The Swedish two-county trial of mammographic screening for breast cancer: recent results on mortality and tumour characteristics; 4. The Malmö mammographic screening trial; 5. The Canadian national breast screening study; 6. The USSR/Germany/WHO BSE study and global strategies for the control of breast cancer; 7. A cost-effectiveness approach to breast cancer screening; 8. Summary of the discussion on breast cancer screening; Part II. Screening for Colorectal Cancer: State of the Art on Screening for Colorectal Cancer: 9. Colon cancer control study: status and current issues; 10. An update on the Nottingham trial of faecal occult blood screening and rescreening of 51 325 subject; 12. Interim report on a randomised trial of screening for colorectal cancer with Hemoccult-II; 13. Case-control evaluation of colorectal cancer screening in the Federal Republic of Germany; 14. Summary of the discussion on colorectal cancer screening; Part III. Screening of Cancer for the Cervix: State of the Art on Screening for Cancer of the Cervix: 15. The natural history of cancer of the cervix, and the implications for screening policy; 16. Effect of organized screening on the risk of cervical cancer in the Nordic countries; 17. The organisation of cervical screening in England and Wales; 18. Indications for colposcopy from a UK viewpoint; 19. Screening for cervix cancer in developing countries; 20. Summary of the discussion on screening for cancer of the cervix; Part IV. Screening for Ovarian Cancer: State of the Art on Screening for Ovarian Cancer: 21. Tumour markers in screening for ovarian cancer; 22. Phase I investigation for early diagnosis of ovarian carcinoma; what problems are to be expected in a larger screening programme?; 23. Screening for ovarian cancer; 24. Summary of the discussion on screening for ovarian cancer; Part V. Screening for Malignant Melanoma: State of the Art on Screening for Melanoma: 25. Screening and early diagnosis for melanoma in Australia and New Zealand; 26. Screening for melanoma in the UK; 27. Screening for melanoma/skin cancer in the United States; 28. The dysplastic naevus syndrome: implications for screening; 29. Summary of the discussion on screening for melanoma of the skin; Part VI. Screening for Prostate Cancer: State of the Art on Screening for Prostate Cancer: 30. Issue in screening for prostate cancer; 31. Available screening tests for prostate cancer; 32. Evaluation of screening for prostate, lung and colorectal cancers :the PLC trial; 33. Summary of the discussion on screening for cancer of the prostate; Part VII. Screening for Neuroblastoma: State of the Art on Screening for Neuroblastoma: 34. Neuroblastoma: studies in Japan; 35. Screening for neuroblastoma, background, preliminary experience in the North of England and proposals for an evaluative study; 36. Summary of the discussion on screening for neuroblastoma; Part VIII. Screening for Stomach Cancer: State of the Art on Screening for Stomach Cancer: 37. Evaluation of mass screening programme for stomach cancer in Japan; 38. Summary for the discussion of screening for stomach cancer; Part IX. Screening for Nasopharyngeal Cancer: State of the Art on Screening for Nasopharyngeal Cancer: 39. Screening for nasopharyngeal carcinoma; 40. Summary of the discussion on screening for nasopharyngeal cancer; Part X. Methodological Issues: 41. Surrogate measures in the design of breast screening trials; 42. Recent developments in cancer screening modeling; 43. Case-control studies of screening; 44. Summary of the discussion on new approaches to the evaluation of screening.